Eli Lilly will acquire the WUSTL-linked neurological disease therapy developer in a $135m deal that could top $1.2bn with milestone payments.
Eli Lilly has agreed to buy Disarm Therapeutics, a US-based neurological disease drug developer based on Washinton University in St Louis (WUSTL) research, for an upfront fee of $135m.
Disarm is working on treatments for neurological disorders such as multiple sclerosis or amyotrophic lateral sclerosis (ALS) that are intended to work by inhibiting the SARM1 protein, thought to be a prime driver of axonal degeneration in the early stages of such diseases.
The company was founded by venture…
